reports
- Jonathan Moreland
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
HPP HUDSON PACIFIC PROPERTIES INC.
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
MOD MODINE MANUFACTURING COMPANY
GLP GLOBAL PARTNERS LP
CDXS CODEXIS
BUSE FIRST BUSEY CORPORATION
AMPH AMPHASTAR PHARMACEUTICALS INC
PZG PARAMOUNT GOLD NEVADA CORP.
GIII G-III APPAREL GROUP LTD.
OXM OXFORD INDUSTRIES INC.
CIA CITIZENS INC. CL A
FLL FULL HOUSE RESORTS INC.
ALOT
MLP ASTRONOVA INC.
BCBP MAUI LAND & PINEAPPLE CO. INC.
BRT BCB BANCORP INC.
STKL BRT APARTMENTS
RSSS SUNOPTA
BWB INC.
BHC RESEARCH SOLUTIONS
SONO BRIDGEWATER BANCSHARES
AMPY BAUSCH HEALTH COMPANIES INC.
ENX SONOS
WSC AMPLIFY ENERGY
DLHC EATON VANCE NEW YORK MUNICIPAL BOND FUND
GRNT WILLSCOT MOBILE MINI HOLDINGS CORP
NUVB DALEIGH HOLDINGS CORP
XLO GRANIT SKOPKE
NVCT NUVATION BIO INC (A)
TCBX XILIO THERAPEUTICS INC
BARK NUVECTIS PHARMA INC
OPAL THIRD COAST BANCSHARES INC
GTE ORIGINAL BARK CO
SRM OPAL FUELS INC
MNR GRAN TIERRA ENERGY INC.
SDHC SRM ENTERTAINMENT INC
NCDL MACH NATURAL RESOURCES LP
SUNS SMITH DOUGLAS HOMES CORP
EVM NUVEEN CHURCHILL DIRECT LENDING CORP
LION SUNRISE REALTY TRUST
HYMC EATON VANCE INSD CALIF MUN BD FD
LIONSGATE STUDIOS CORP
HYCROFT MINING HOLDING CORPORATION
- Jonathan Moreland
PZG PARAMOUNT GOLD NEVADA CORP.
GIII G-III APPAREL GROUP LTD.
CIA CITIZENS INC. CL A
RSSS RESEARCH SOLUTIONS
BWB BRIDGEWATER BANCSHARES
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
NUVB NUVATION BIO INC (A)
XLO XILIO THERAPEUTICS INC
EVM EATON VANCE INSD CALIF MUN BD FD
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthc...
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York WEST CHESTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference in New York City. Jefferies Global Healthcare Conference, June 3-5, 2025Event details:Date:...
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results – Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarter, the most in company history and a 16.7% growth over Q4’24 – – Late-stage pipeline continues to advance with completion of end-of-Phase 2 meeting with Food and Drug Administration for VP-315, Verrica’s candidate for basal cell carcinoma, and continued advancement towards initiation of global Phase 3 program in common warts (VP-102/YCANTH) with partner Torii Pharmaceuti...
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Tri...
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development On-track to enable initiation of a clinical trial in ALS patients in late 2025 BOTHELL, Wash., May 13, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to r...
HighPeak Energy, Inc. Announces First Quarter 2025 Financial and Opera...
HighPeak Energy, Inc. Announces First Quarter 2025 Financial and Operating Results - AMENDED FORT WORTH, Texas, May 12, 2025 (GLOBE NEWSWIRE) -- HighPeak Energy, Inc. (“HighPeak” or the “Company”) (NASDAQ: HPK) today announced amended financial and operating results for the quarter ended March 31, 2025, provided an updated 2025 development outlook and increased production guidance. Please note that in the Unaudited Condensed Consolidated Statements of Cash Flows table, the amount of Repayments under Term Loan Credit Agreement for 2025 was amended from (120,000) to (30,000). The amended r...
HighPeak Energy, Inc. Announces First Quarter 2025 Financial and Opera...
HighPeak Energy, Inc. Announces First Quarter 2025 Financial and Operating Results FORT WORTH, Texas, May 12, 2025 (GLOBE NEWSWIRE) -- HighPeak Energy, Inc. (“HighPeak” or the “Company”) (NASDAQ: HPK) today announced financial and operating results for the quarter ended March 31, 2025, provided an updated 2025 development outlook and increased production guidance. First Quarter 2025 Highlights Sales volumes averaged approximately 53.1 thousand barrels of crude oil equivalent per day (“MBoe/d”), representing a 6% increase from the fourth quarter 2024.Net income was $36.3 mill...
Athira Pharma Reports First Quarter 2025 Financial Results and Pipelin...
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 On-track to enable dosing ALS patients in late 2025 BOTHELL, Wash., May 09, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ...
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results...
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025 WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 13, 2025, to discuss the Company's financial results for the first quarter ending March 31, 2025, and provide a corporate update. Individual...
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences C...
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Citizens Life Sciences Conference in New York City. Citizens Life Sciences Conference, May 7-8, 2025Event details:Date: Wednesday, Ma...
HighPeak Energy, Inc. Announces 2025 First Quarter Earnings Release an...
HighPeak Energy, Inc. Announces 2025 First Quarter Earnings Release and Conference Call Dates FORT WORTH, Texas, April 29, 2025 (GLOBE NEWSWIRE) -- HighPeak Energy, Inc. (NASDAQ: HPK) (“HighPeak Energy”), today announced that it plans to release its 2025 first quarter financial and operating results after the close of trading on Monday, May 12, 2025. HighPeak Energy will host a conference call and webcast on Tuesday, May 13, 2025 at 10:00 a.m. Central Time for investors and analysts to discuss its 2025 first quarter financial results and operational highlights. Participants may register ...
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Di...
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025 – Company generated quarterly sequential growth with Q1 YCANTH® dispensed applicator units rising above 10,000 for the first time in a quarter – – As YCANTH distributor inventory levels have normalized, Company expects that dispensed applicator units will now more closely track demand and gross revenue – WEST CHESTER, Pa., April 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company...
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of ...
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Gavin Corcoran, M.D. to its Board of Directors. “We are pleased to welcome Dr. Gavin Corcoran to our Board of Directors,” said Jayson Rieger, Ph.D., MBA, President and Chief Executive Officer of Verrica Pharmaceuticals. “Gavin is a highly a...
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virt...
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference WEST CHESTER, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference. 24th Annual Needham Virtual Healthcare Conference, Apri...
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Med...
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Noah L. Rosenberg, M.D., as Chief Medical Officer. “We are excited to welcome Noah Rosenberg to the Verrica team as our new Chief Medical Officer,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “As a highl...
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Fina...
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results – Company generated quarterly sequential growth in YCANTH® dispensed applicator units of 12.3% in Q4’24 concurrent with significantly lower operating expenses – – Company reports positive quarterly revenue earlier than previously disclosed expectations, as new demand resulted in Company’s primary distribution partner ordering applicators of YCANTH during Q4’24 – – Late-stage pipeline continues to advance with programs in basal cell carcinoma (VP-315) and common warts (VP-102/YCANTH) – – Recent...
HighPeak Energy, Inc. Announces Fourth Quarter and Year-End 2024 Finan...
HighPeak Energy, Inc. Announces Fourth Quarter and Year-End 2024 Financial and Operating Results and Provides 2025 Guidance FORT WORTH, Texas, March 10, 2025 (GLOBE NEWSWIRE) -- HighPeak Energy, Inc. (“HighPeak” or the “Company”) (NASDAQ: HPK) today announced financial and operating results for the quarter and the year ended December 31, 2024. In addition, HighPeak provided its 2025 guidance and capital budget, as approved by its Board of Directors. Highlights 2024 sales volumes averaged approximately 50.0 thousand barrels of crude oil equivalent per day (“MBoe/d”), representing a 10% i...
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Fi...
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025 WEST CHESTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, March 11, 2025, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2024, and ...
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline an...
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS) On-track to enable dosing ALS patients in 2025 BOTHELL, Wash., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2024, and provided recent pipeline and bus...
Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Hea...
Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston WEST CHESTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston. TD Cowen 45th Annual Health Care Conference, Mar...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.